Base de dados : MEDLINE
Pesquisa : D12.644.861.695 [Categoria DeCS]
Referências encontradas : 1982 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 199 ir para página                         

  1 / 1982 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28353655
[Au] Autor:Kim Y; Keogh JB; Clifton PM
[Ad] Endereço:School of Pharmacy and Medical Sciences, University of South Australia, Adelaide SA 5001, Australia. yoona.kim@mymail.unisa.edu.au.
[Ti] Título:Effects of Two Different Dietary Patterns on Inflammatory Markers, Advanced Glycation End Products and Lipids in Subjects without Type 2 Diabetes: A Randomised Crossover Study.
[So] Source:Nutrients;9(4), 2017 Mar 29.
[Is] ISSN:2072-6643
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Epidemiological studies suggest that consumption of red and processed meat and refined grains are associated with type 2 diabetes and metabolic syndrome and increased inflammatory and fibrinolytic markers. We hypothesised that a diet high in red and processed meat and refined grains (HMD) would increase inflammatory markers and advanced glycation end products (AGEs) compared with a diet high in dairy, whole grains, nuts and legumes (HWD). We performed a randomised crossover study of two four-week interventions in 51 participants without type 2 diabetes (15 men and 36 women aged 35.1 ± 15.6 years; body mass index: 27.7 ± 6.9 kg/m²). No baseline measurements were performed. Plasma fluorescent AGEs, carboxymethyllysine, glucose, insulin, lipids, hs-CRP, interleukin 6 (IL-6) and plasminogen activator inhibitor-1 (PAI-1) were analysed after four weeks on each diet. IL-6, hs-CRP, AGEs and carboxymethyllysine were not different between diets but PAI-1 was higher after the HMD than after HWD ((median and interquartile range) 158, 81 vs. 121, 53 ng/mL < 0.001). PAI-1 on the HWD diet was inversely correlated with whole grains intake ( = 0.007). PAI-1 was inversely correlated with insulin sensitivity index (r = -0.45; = 0.001) and positively correlated with serum total cholesterol (r = 0.35; = 0.012) and serum triglyceride (r = 0.32; = 0.021) on HMD. This trial was registered with the Australian New Zealand Clinical Trials Registry (ACTRN12614000519651).
[Mh] Termos MeSH primário: Diabetes Mellitus Tipo 2/prevenção & controle
Dieta Ocidental
Comportamento Alimentar
Produtos Finais de Glicação Avançada/sangue
Dieta Saudável
Inflamação/etiologia
Lipídeos/sangue
[Mh] Termos MeSH secundário: Adulto
Biomarcadores/sangue
Colesterol/sangue
Estudos Cross-Over
Diabetes Mellitus Tipo 2/sangue
Feminino
Manipulação de Alimentos
Seres Humanos
Inflamação/sangue
Resistência à Insulina
Lisina/análogos & derivados
Lisina/sangue
Masculino
Meia-Idade
Inativadores de Plasminogênio/sangue
Valores de Referência
Triglicerídeos/sangue
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Biomarkers); 0 (Glycation End Products, Advanced); 0 (Lipids); 0 (Plasminogen Inactivators); 0 (Triglycerides); 70YDX3Z2O7 (N(6)-carboxymethyllysine); 97C5T2UQ7J (Cholesterol); K3Z4F929H6 (Lysine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170330
[St] Status:MEDLINE


  2 / 1982 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27556351
[Au] Autor:Flevaris P; Vaughan D
[Ad] Endereço:Department of Medicine, Northwestern University, Chicago, Illinois.
[Ti] Título:The Role of Plasminogen Activator Inhibitor Type-1 in Fibrosis.
[So] Source:Semin Thromb Hemost;43(2):169-177, 2017 Mar.
[Is] ISSN:1098-9064
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Extracellular matrix (ECM) deposition during wound healing is a physiological response to an insult. Wound healing becomes deregulated in the setting of chronic injury or long-standing metabolic disease, leading to the accumulation of ECM components and fibrosis. Matrix protein turnover is determined by the rate of synthesis as well as the rate of proteolytic degradation and clearance by matrix metalloproteinases (MMPs). The persistent activation of interstitial myofibroblasts, coupled with defects in matrix proteolysis, ultimately disrupts tissue architecture and leads to biochemical and mechanical organ dysfunction with eventual organ failure. Plasminogen activator inhibitor type-1 (PAI-1) regulates tissue homeostasis and wound healing by inhibiting plasmin-mediated MMP activation. Multiple reports using models of liver, lung, and kidney fibrosis suggest that PAI-1 deficiency or inhibition of PAI-1 activity attenuates fibrosis. The disinhibition of plasmin-mediated MMP activation leads to collagen degradation and its diminished accumulation, resulting in the reduction of fibrotic matrix deposition in these organs. Paradoxically, homozygous deficiency of PAI-1 promotes age-dependent spontaneous cardiac fibrosis, suggesting a protective role for PAI-1 in the heart. It remains unclear whether PAI-1-deficient cardiac fibroblasts have increased proliferative, migratory, or differentiation capabilities, that allow them to overcome increased plasmin and MMP activity and matrix clearance. In this review, we examine the specific roles of PAI-1 in fibrosis of different organs including the lung, liver, kidney, and cardiovascular system.
[Mh] Termos MeSH primário: Fibrose/tratamento farmacológico
Transtornos Hemorrágicos/terapia
Inibidor 1 de Ativador de Plasminogênio/deficiência
Inativadores de Plasminogênio/uso terapêutico
[Mh] Termos MeSH secundário: Fibrose/patologia
Seres Humanos
Inibidor 1 de Ativador de Plasminogênio/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Plasminogen Activator Inhibitor 1); 0 (Plasminogen Inactivators); 0 (SERPINE1 protein, human)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170502
[Lr] Data última revisão:
170502
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160825
[St] Status:MEDLINE
[do] DOI:10.1055/s-0036-1586228


  3 / 1982 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28195067
[Au] Autor:Marlicz W; Wunsch E; Mydlowska M; Milkiewicz M; Serwin K; Mularczyk M; Milkiewicz P; Raszeja-Wyszomirska J
[Ad] Endereço:Department of Gastroenterology, Pomeranian Medical University, Szczecin, Poland. marlicz@hotmail.com.
[Ti] Título:The effect of short term treatment with probiotic VSL#3 on various clinical and biochemical parameters in patients with liver cirrhosis.
[So] Source:J Physiol Pharmacol;67(6):867-877, 2016 Dec.
[Is] ISSN:1899-1505
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:The evidence is mounting that alterations of innate immunity and gut microbiota contribute to chronic liver disease and its complications. Modulation of intestinal microbiota is an emerging therapeutic strategy in hepatology. Probiotics through modulation of intestinal milieu have the potential to affect the course of liver disease. The data concerning the influence of probiotics on various plasma molecules and compounds involved in the pathogenesis of hyperdynamic circulatory state in liver cirrhosis is still not confluent and require further evaluation. In our study twenty patients with compensated and decompensated liver cirrhosis and ten healthy controls received probiotic VSL#3 daily for 28 days. Plasma levels of interleukin 6 (IL-6), vascular endothelial growth factor (VEGF), plasminogen activator inhibitor (PAI), macrophage inflammatory protein 3/α (MIP-3 α/CCL20), monocyte chemotactic protein-1α (MCP-1/CCL2), human myeloperoxidase (MPO), nitric oxide (NO), prostaglandins, thromboxane (TXB ) and big-endothelin were measured at baseline, day 14 and 28 of probiotic administration. The incidence of hepatic encephalopathy was assessed with critical flicker frequency. Changes in clinical, biochemical and microbiological parameters were evaluated. The stage of liver cirrhosis correlated with an increase in plasma levels of pro-inflammatory cytokines (IL-6) and chemotactic chemokines involved in immune cell trafficking (MIP-3α/CCL20). Probiotic administration in patients with liver cirrhosis led to modulation of plasma levels of several molecules and compounds measured (MIP-3α/CCL20, NO, big-endothelin, TXB and MPO). The grade of encephalopathy during the course of probiotic supplementation remained unaffected in both groups of patients. VSL#3 treatment was well tolerated and safe in patients with liver disease. In patients with compensated and decompensated liver cirrhosis, VSL#3 manipulates selected plasma molecules and compounds involved in hyperdynamic circulatory dysfunction. Short term VSL#3 administration affects several clinical and biochemical parameters commonly altered in liver cirrhosis.
[Mh] Termos MeSH primário: Microbioma Gastrointestinal/efeitos dos fármacos
Cirrose Hepática/metabolismo
Probióticos/administração & dosagem
[Mh] Termos MeSH secundário: Adulto
Quimiocina CCL2/metabolismo
Quimiocina CCL20/metabolismo
Quimiocinas/metabolismo
Endotelinas/metabolismo
Feminino
Encefalopatia Hepática/patologia
Seres Humanos
Imunidade Inata/efeitos dos fármacos
Interleucina-6/metabolismo
Intestinos/microbiologia
Cirrose Hepática/microbiologia
Masculino
Meia-Idade
Óxido Nítrico/metabolismo
Peroxidase/metabolismo
Inativadores de Plasminogênio/metabolismo
Prostaglandinas/metabolismo
Tromboxanos/metabolismo
Fator A de Crescimento do Endotélio Vascular/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (CCL20 protein, human); 0 (Chemokine CCL2); 0 (Chemokine CCL20); 0 (Chemokines); 0 (Endothelins); 0 (IL6 protein, human); 0 (Interleukin-6); 0 (Plasminogen Inactivators); 0 (Prostaglandins); 0 (Thromboxanes); 0 (Vascular Endothelial Growth Factor A); 31C4KY9ESH (Nitric Oxide); EC 1.11.1.7 (Peroxidase)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170608
[Lr] Data última revisão:
170608
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170215
[St] Status:MEDLINE


  4 / 1982 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27534235
[Au] Autor:Soejima H; Ogawa H
[Ti] Título:[RAS inhibitors].
[So] Source:Nihon Rinsho;74 Suppl 4 Pt 1:586-90, 2016 Jun 20.
[Is] ISSN:0047-1852
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Mh] Termos MeSH primário: Sistema Renina-Angiotensina/efeitos dos fármacos
[Mh] Termos MeSH secundário: Biomarcadores/análise
Doença das Coronárias/sangue
Seres Humanos
Peptidil Dipeptidase A
Ativadores de Plasminogênio
Inativadores de Plasminogênio
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Plasminogen Inactivators); EC 3.4.15.1 (Peptidyl-Dipeptidase A); EC 3.4.21.- (Plasminogen Activators)
[Em] Mês de entrada:1609
[Cu] Atualização por classe:160818
[Lr] Data última revisão:
160818
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160819
[St] Status:MEDLINE


  5 / 1982 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27434823
[Au] Autor:Dietrich K; Ball GD; Mitchell LG
[Ad] Endereço:University of Alberta, Edmonton, AB, Canada.
[Ti] Título:Increased plasminogen activator inhibitor results in a hypofibrinolytic state in adolescents with obesity: in vivo and ex vivo evidence.
[So] Source:Br J Haematol;175(2):300-307, 2016 Oct.
[Is] ISSN:1365-2141
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Obesity in adolescents increases their risk for deep vein thrombosis. The objectives of this study were to determine potential mechanisms for thrombotic risk by investigating the fibrinolytic pathway in a sample of adolescents with and without obesity. Thirty-seven adolescents with obesity and 16 normal weight age-matched controls were recruited. Plasma levels of components of the fibrinolytic system were measured in addition to a Global Haemostasis Potential assay (GHP), which assesses plasma capacity to generate and lyse a fibrin clot. Levels of plasminogen activator inhibitor (PAI) and tissue plasminogen activator (tPA)/PAI complexes were increased in adolescents with obesity when compared to normal weight controls. There was a significant inverse association of increasing PAI with a decrease in plasmin-antiplasmin complexes. The GHP in obese adolescents displayed a hypofibrinolytic response with a markedly increased t clot lysis time, as well as an increase in fibrin clot density as indicated by increased absorbance at maximum peak height. In the obese group, immunodepletion of PAI decreased both t lysis time and absorbance at maximum peak height. We have shown in vivo and ex vivo there is a hypofibrinolytic state in obese adolescents and have established the hypofibrinolytic state is due to increased PAI levels.
[Mh] Termos MeSH primário: Fibrinólise
Obesidade/sangue
Inativadores de Plasminogênio/sangue
[Mh] Termos MeSH secundário: Adolescente
Biomarcadores
Coagulação Sanguínea
Testes de Coagulação Sanguínea
Estudos de Casos e Controles
Criança
Feminino
Hemostasia
Seres Humanos
Mediadores da Inflamação/sangue
Masculino
Ativador de Plasminogênio Tecidual/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Inflammation Mediators); 0 (Plasminogen Inactivators); EC 3.4.21.68 (Tissue Plasminogen Activator)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170515
[Lr] Data última revisão:
170515
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160720
[St] Status:MEDLINE
[do] DOI:10.1111/bjh.14238


  6 / 1982 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27059485
[Au] Autor:Zhang YY; Zhou HF; Yang JH; He Y; Chen XQ; Nishinari K; Wan HF; Wan HT
[Ad] Endereço:Research Institution of Cardio-Cerebral-Vascular Disease, Zhejiang University of Traditional Chinese Medicine, Hangzhou, 310053, China.
[Ti] Título:Effects of Danhong Injection (丹红注射液) and its main components on anticoagulation and fibrinolysis in cultured vein endothelial cells.
[So] Source:Chin J Integr Med;22(4):276-83, 2016 Apr.
[Is] ISSN:1672-0415
[Cp] País de publicação:China
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To observe the effects of Danhong Injection (丹红注射液) and its main components, including daiclzein and hydroxysafflor yellow A (HSYA), on the anticoagulation, fibrinolysis, anti-apoptosis in hypoxia model of vein endothelial cells (VECs). METHODS: VECs were prepared and were put in a hypoxia environment, which consisted of mixed gas of 95% N and 5% CO mixed gas, when reached confluent culture. Five groups used different treatments, including normal control group, hypoxia group, daiclzein group, HSYA group and Danhong Injection group. The VECs were identified by fluorescence double labeling methods. The morphology was observed by a phase contrast microscopy. The effects of Danhong Injection, daiclzein and HSYA on 6 keto prostaglandin F1α (6-keto-PGF1α) level was measured by the method of radioimmunoassay (RIA). Superoxide dismutase (SOD) activity was tested by water soluble tetrazolium salt. The content of malondialdehyde (MDA) was measured by thiobarbituric acid. The activities of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI) were measured by the method of chromogenic substrate. The contents of endothelin (ET) and nitric oxide (NO) were detected by non-equilibrium RIA and enzymelinked immunosorbent assay. Cells apoptosis rate was determined by flow cytometry. RESULTS: Compared with the normal control group, the floating cells number, PAI activity, ET and MDA contents, and cells apoptosis rate in the culture solution of hypoxia group were all significantly increased, whereas the 6-keto-PGF1α and NO contents, and t-PA and SOD activities were decreased significantly (P<0.01). Compared with the hypoxia group, Danhong Injection markedly increased the 6-keto-PGF1α content and SOD activity, regulated PAI and t-PA activities, ET and NO contents, and decreased MDA content and cells apoptosis rate (P<0.05 or P<0.01). CONCLUSIONS: Danhong Injection and its main components played an important role in protecting primary VECs from hypoxic damage by regulating the secretion and vasomotor function of VECs. The function of Danhong Injection was most remarkable.
[Mh] Termos MeSH primário: Coagulação Sanguínea/efeitos dos fármacos
Medicamentos de Ervas Chinesas/farmacologia
Células Endoteliais/metabolismo
Fibrinólise/efeitos dos fármacos
Veias Umbilicais/citologia
[Mh] Termos MeSH secundário: 6-Cetoprostaglandina F1 alfa/metabolismo
Animais
Apoptose/efeitos dos fármacos
Contagem de Células
Células Cultivadas
Células Endoteliais/efeitos dos fármacos
Endotelinas/metabolismo
Fator VIII/metabolismo
Imunofluorescência
Seres Humanos
Recém-Nascido
Injeções
Malondialdeído/metabolismo
Óxido Nítrico/metabolismo
Inativadores de Plasminogênio/metabolismo
Coelhos
Superóxido Dismutase/metabolismo
Ativador de Plasminogênio Tecidual/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Drugs, Chinese Herbal); 0 (Endothelins); 0 (Plasminogen Inactivators); 0 (danhong); 31C4KY9ESH (Nitric Oxide); 4Y8F71G49Q (Malondialdehyde); 58962-34-8 (6-Ketoprostaglandin F1 alpha); 9001-27-8 (Factor VIII); EC 1.15.1.1 (Superoxide Dismutase); EC 3.4.21.68 (Tissue Plasminogen Activator)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:171105
[Lr] Data última revisão:
171105
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160410
[St] Status:MEDLINE
[do] DOI:10.1007/s11655-016-2498-x


  7 / 1982 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27016834
[Au] Autor:Montazer-Torbati F; Boutinaud M; Brun N; Richard C; Neveu A; Jaffrézic F; Laloë D; LeBourhis D; Nguyen M; Chadi S; Jammes H; Renard JP; Chat S; Boukadiri A; Devinoy E
[Ad] Endereço:INRA, UMR1313 GABI, F-78350 Jouy-en-Josas, France.
[Ti] Título:Differences during the first lactation between cows cloned by somatic cell nuclear transfer and noncloned cows.
[So] Source:J Dairy Sci;99(6):4778-4794, 2016 Jun.
[Is] ISSN:1525-3198
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Lactation performance is dependent on both the genetic characteristics and the environmental conditions surrounding lactating cows. However, individual variations can still be observed within a given breed under similar environmental conditions. The role of the environment between birth and lactation could be better appreciated in cloned cows, which are presumed to be genetically identical, but differences in lactation performance between cloned and noncloned cows first need to be clearly evaluated. Conflicting results have been described in the literature, so our aim was to clarify this situation. Nine cloned Prim' Holstein cows were produced by the transfer of nuclei from a single fibroblast cell line after cell fusion with enucleated oocytes. The cloned cows and 9 noncloned counterparts were raised under similar conditions. Milk production and composition were recorded monthly from calving until 200d in milk. At 67d in milk, biopsies were sampled from the rear quarter of the udder, their mammary epithelial cell content was evaluated, and mammary cell renewal, RNA, and DNA were then analyzed in relevant samples. The results showed that milk production did not differ significantly between cloned and noncloned cows, but milk protein and fat contents were less variable in cloned cows. Furthermore, milk fat yield and contents were lower in cloned cows during early lactation. At around 67 DIM, milk fat and protein yields, as well as milk fat, protein, and lactose contents, were also lower in cloned cows. These lower yields could be linked to the higher apoptotic rate observed in cloned cows. Apoptosis is triggered by insulin-like factor growth binding protein 5 (IGFBP5) and plasminogen activator inhibitor (PAI), which both interact with CSN1S2. During our experiments, CSN1S2 transcript levels were lower in the mammary gland of cloned cows. The mammary cell apoptotic rate observed in cloned cows may have been related to the higher levels of DNA (cytosine-5-)-methyltransferase 1 (DNMT1) transcripts, coding for products that maintain the epigenetic status of cells. We conclude, therefore, that milk production in cloned cows differs slightly from that of noncloned cows. These differences may be due, in part, to a higher incidence of subclinical mastitis. They were associated with differences in cell apoptosis and linked to variations in DNMT1 mRNA. However, milk protein and fat contents were more similar among cloned cows than among noncloned cows.
[Mh] Termos MeSH primário: Clonagem de Organismos
Transferência Embrionária/veterinária
Lactação
Glândulas Mamárias Animais/citologia
[Mh] Termos MeSH secundário: Animais
Apoptose
Bovinos
Células Cultivadas
DNA (Citosina-5-)-Metiltransferase 1
DNA (Citosina-5-)-Metiltransferases/genética
DNA (Citosina-5-)-Metiltransferases/metabolismo
Gorduras na Dieta/análise
Epigênese Genética
Feminino
Proteína 5 de Ligação a Fator de Crescimento Semelhante à Insulina/genética
Proteína 5 de Ligação a Fator de Crescimento Semelhante à Insulina/metabolismo
Lactose/análise
Glândulas Mamárias Animais/metabolismo
Leite/química
Leite/secreção
Proteínas do Leite/análise
Inativadores de Plasminogênio/genética
Inativadores de Plasminogênio/metabolismo
RNA Mensageiro/genética
RNA Mensageiro/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Dietary Fats); 0 (Insulin-Like Growth Factor Binding Protein 5); 0 (Milk Proteins); 0 (Plasminogen Inactivators); 0 (RNA, Messenger); EC 2.1.1.37 (DNA (Cytosine-5-)-Methyltransferase 1); EC 2.1.1.37 (DNA (Cytosine-5-)-Methyltransferases); J2B2A4N98G (Lactose)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160328
[St] Status:MEDLINE


  8 / 1982 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26702150
[Au] Autor:Liu RM; Eldridge S; Watanabe N; Deshane J; Kuo HC; Jiang C; Wang Y; Liu G; Schwiebert L; Miyata T; Thannickal VJ
[Ad] Endereço:Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama; rliu@uab.edu.
[Ti] Título:Therapeutic potential of an orally effective small molecule inhibitor of plasminogen activator inhibitor for asthma.
[So] Source:Am J Physiol Lung Cell Mol Physiol;310(4):L328-36, 2016 Feb 15.
[Is] ISSN:1522-1504
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Asthma is one of the most common respiratory diseases. Although progress has been made in our understanding of airway pathology and many drugs are available to relieve asthma symptoms, there is no cure for chronic asthma. Plasminogen activator inhibitor 1 (PAI-1), a primary inhibitor of tissue-type and urokinase-type plasminogen activators, has pleiotropic functions besides suppression of fibrinolysis. In this study, we show that administration of TM5275, an orally effective small-molecule PAI-1 inhibitor, 25 days after ovalbumin (OVA) sensitization-challenge, significantly ameliorated airway hyperresponsiveness in an OVA-induced chronic asthma model. Furthermore, we show that TM5275 administration significantly attenuated OVA-induced infiltration of inflammatory cells (neutrophils, eosinophils, and monocytes), the increase in the levels of OVA-specific IgE and Th2 cytokines (IL-4 and IL-5), the production of mucin in the airways, and airway subepithelial fibrosis. Together, the results suggest that the PAI-1 inhibitor TM5275 may have therapeutic potential for asthma through suppressing eosinophilic allergic response and ameliorating airway remodeling.
[Mh] Termos MeSH primário: Remodelação das Vias Aéreas/efeitos dos fármacos
Asma/tratamento farmacológico
Piperazinas/uso terapêutico
Inativadores de Plasminogênio/uso terapêutico
para-Aminobenzoatos/uso terapêutico
[Mh] Termos MeSH secundário: Animais
Asma/patologia
Citocinas/biossíntese
Eosinófilos/efeitos dos fármacos
Feminino
Fibrinólise/efeitos dos fármacos
Ovalbumina/administração & dosagem
Ovalbumina/uso terapêutico
Piperazinas/administração & dosagem
Inativadores de Plasminogênio/administração & dosagem
para-Aminobenzoatos/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
0 (5-chloro-2-(((2-(4-(diphenylmethyl)piperazin-1-yl)-2-oxoethoxy)acetyl)amino)benzoate); 0 (Cytokines); 0 (Piperazines); 0 (Plasminogen Inactivators); 0 (para-Aminobenzoates); 9006-59-1 (Ovalbumin)
[Em] Mês de entrada:1607
[Cu] Atualização por classe:170215
[Lr] Data última revisão:
170215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151225
[St] Status:MEDLINE
[do] DOI:10.1152/ajplung.00217.2015


  9 / 1982 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26452123
[Au] Autor:Sonig A; Lin N; Krishna C; Natarajan SK; Mokin M; Hopkins LN; Snyder KV; Levy EI; Siddiqui AH
[Ad] Endereço:Departments of 1 Neurosurgery.
[Ti] Título:Impact of transfer status on hospitalization cost and discharge disposition for acute ischemic stroke across the US.
[So] Source:J Neurosurg;124(5):1228-37, 2016 May.
[Is] ISSN:1933-0693
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECT In this study, the authors used information provided in the Nationwide Inpatient Sample (NIS) to study the impact of transferring stroke patients from one facility to a center where they received some form of active stroke intervention (intravenous tissue plasminogen activator, thrombectomy, or a combination of both therapies). METHODS Patient demographic characteristics and hospital factors obtained from the 2008-2010 acute stroke NIS data were analyzed. Discharge disposition, hospitalization cost, and mortality were the dependent variables studied. Univariate analysis and multivariate binary logistic regression analysis were performed. Data analysis focused on the cohort of acute stroke patients who received some form of active intervention (55,913 of 1,311,511 patients in the NIS). RESULTS When overall outcome was considered, transferred patients had a significantly higher number of other-than-routine (OTR, i.e., other than discharge to home without home health care) discharge dispositions (p < 0.0001). In multivariate regression analysis including pertinent patient and hospital factors, transfer-in patients had significantly worse OTR discharge disposition (p < 0.0001, odds ratio [OR] 2.575, 95% CI 2.341-2.832). Mean hospitalization cost including an intervention was $70,325.11 for direct admissions and $97,546.92 for transferred patients. Transfer from another facility (p < 0.001, OR 1.677, 95% CI 1.548-1.817) was associated with higher hospitalization cost. CONCLUSIONS The study showed that hospital cost for acute stroke intervention is significantly higher for a transferred patient than for a direct admission. Moreover, the frequency of OTR discharge was significantly higher among transferred patients than direct admissions. Future strategies should focus on ways and means of transporting patients appropriately and directly to stroke centers.
[Mh] Termos MeSH primário: Custos Hospitalares
Hospitalização/economia
Alta do Paciente/economia
Transferência de Pacientes/economia
Acidente Vascular Cerebral/economia
Acidente Vascular Cerebral/terapia
[Mh] Termos MeSH secundário: Doença Aguda
Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Criança
Estudos de Coortes
Terapia Combinada/economia
Custos e Análise de Custo
Feminino
Seres Humanos
Masculino
Meia-Idade
Inativadores de Plasminogênio/economia
Inativadores de Plasminogênio/uso terapêutico
Acidente Vascular Cerebral/mortalidade
Análise de Sobrevida
Trombectomia/economia
Terapia Trombolítica/economia
Estados Unidos
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Plasminogen Inactivators)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:151010
[St] Status:MEDLINE
[do] DOI:10.3171/2015.4.JNS141631


  10 / 1982 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25128822
[Au] Autor:Banks WA; Abrass CK; Hansen KM
[Ad] Endereço:Geriatrics Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, Washington. Division of Gerontology and Geriatric Medicine, Department of Internal Medicine, University of Washington School of Medicine, Seattle. wabanks1@uw.edu.
[Ti] Título:Differentiating the Influences of Aging and Adiposity on Brain Weights, Levels of Serum and Brain Cytokines, Gastrointestinal Hormones, and Amyloid Precursor Protein.
[So] Source:J Gerontol A Biol Sci Med Sci;71(1):21-9, 2016 Jan.
[Is] ISSN:1758-535X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Aging and obesity exert important effects on disease. Differentiating these effects is difficult, however, because weight gain often accompanies aging. Here, we used a nested design of aged, calorically restricted, and refed rats to measure changes in brain and blood levels of cytokines and gastrointestinal hormones, brain amyloid precursor protein levels, and brain and body weights. By comparing groups and using path analysis, we found divergent influences of chronological aging versus body weight, our main findings being (i) changes in whole brain weight and serum macrophage colony-stimulating factor levels correlated better with body weight than with chronological aging, (ii) a decrease in brain cytokines and brain plasminogen activator inhibitor levels correlated better with chronological aging than with body weight, (iii) serum erythropoietin levels were influenced by both body weight and aging, (iv) serum plasminogen activator inhibitor, serum cytokines, and brain tumor necrosis factor were not influenced by aging or body weight, and (v) brain amyloid precursor protein more closely related to body weight and serum levels of gastrointestinal hormones than to brain weight, chronological aging, or cytokines. These findings show that although aging and body weight interact, their influences are distinct not only among various cytokines and hormones but also between the central nervous system and the peripheral tissue compartments.
[Mh] Termos MeSH primário: Tecido Adiposo/metabolismo
Envelhecimento/metabolismo
Precursor de Proteína beta-Amiloide/metabolismo
Peso Corporal/fisiologia
Encéfalo
Leptina/metabolismo
[Mh] Termos MeSH secundário: Animais
Encéfalo/metabolismo
Encéfalo/patologia
Eritropoetina/sangue
Hormônios Gastrointestinais/sangue
Fator Estimulador de Colônias de Macrófagos/sangue
Masculino
Obesidade/metabolismo
Tamanho do Órgão
Inativadores de Plasminogênio/metabolismo
Ratos
Estatística como Assunto
Fator de Necrose Tumoral alfa/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.
[Nm] Nome de substância:
0 (Amyloid beta-Protein Precursor); 0 (Gastrointestinal Hormones); 0 (Leptin); 0 (Plasminogen Inactivators); 0 (Tumor Necrosis Factor-alpha); 11096-26-7 (Erythropoietin); 81627-83-0 (Macrophage Colony-Stimulating Factor)
[Em] Mês de entrada:1604
[Cu] Atualização por classe:170317
[Lr] Data última revisão:
170317
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:140817
[St] Status:MEDLINE
[do] DOI:10.1093/gerona/glu100



página 1 de 199 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde